Section Arrow
EOLS.NASDAQ
- Evolus
Quotes are at least 15-min delayed:2024/11/10 20:00 EST
Last
 13.68
-0.61 (-4.27%)
Day High 
14.35 
Prev. Close
14.29 
1-M High
17.82 
Volume 
1.28M 
Bid
13.24
Ask
14.21
Day Low
13.35 
Open
14.28 
1-M Low
14.255 
Market Cap 
901.62M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 16.33 
20-SMA 16.42 
50-SMA 16.26 
52-W High 17.82 
52-W Low 7.74 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/0.15
Enterprise Value
1.03B
Balance Sheet
Book Value Per Share
0.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
202.09M
Operating Revenue Per Share
2.93
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.49-0.06-3.87%-- 
ESPREsperion Therapeutics2.275+0.165+7.82%-- 
VTRSViatris12.96-0.22-1.67%227.2PE
HLNHaleon plc9.61+0.01+0.10%31.1PE
CGCCanopy Growth Corp4.24-0.31-6.81%-- 
Quotes are at least 15-min delayed:2024/11/10 20:00 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.